Home Cart Sign in  
Chemical Structure| 199596-05-9 Chemical Structure| 199596-05-9

Structure of JIB-04
CAS No.: 199596-05-9

Chemical Structure| 199596-05-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JIB-04 is a pan-selective inhibitor of Jumonji histone demethylases, with IC50s of 230 nM for JARID1A, 340 nM for JMJD2E, 855 nM for JMJD3, 445 nM for JMJD2A, 435 nM for JMJD2B, 1100 nM for JMJD2C, and 290 nM for JMJD2D.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JIB-04

CAS No. :199596-05-9
Formula : C17H13ClN4
M.W : 308.76
SMILES Code : ClC1=CN=C(N/N=C(C2=CC=CC=C2)/C3=NC=CC=C3)C=C1
InChI Key :YHHFKWKMXWRVTJ-OQKWZONESA-N
Pubchem ID :6519698

Safety of JIB-04

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of JIB-04

epigenetics

Isoform Comparison

Biological Activity

Target
  • KDM4

    JMJD2D, IC50:290 nM

    JMJD2E, IC50:435 nM

  • KDM6

    JMJD3, IC50:855 nM

  • KDM5

    JARID1A, IC50:230 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Nalm6 cells 0.5 µM 24 hours JIB-04 increased G9a methylation Cell Death Dis. 2018 Oct 10;9(10):1038.
U1/HIV cells 0.25-1 µM JIB-04 treatment increased HIV-1 Gag mRNA level Nucleic Acids Res. 2019 Aug 22;47(14):7333-7347.
H358 non-small cell lung cancer cells 500 nM 24 hours JIB-04 E-isomer specifically upregulates anti-growth genes and downregulates pro-growth genes in H358 cells, while no similar changes were observed in normal cells. Nat Commun. 2013;4:2035.
HCC4017 non-small cell lung cancer cells 0.5 µM 24 hours JIB-04 E-isomer increased H3K4me3 levels at the c10orf10 promoter in HCC4017 cells. Nat Commun. 2013;4:2035.
LN229 cells 0.1735 µM 24, 48, 72, 96 hours JIB-04 inhibited the proliferation of LN229 cells in a dose-dependent manner. Neuro Oncol. 2024 Apr 5;26(4):653-669.
GBM#P3 cells 1.534 µM 24, 48, 72, 96 hours JIB-04 inhibited the proliferation of GBM#P3 cells in a dose-dependent manner. Neuro Oncol. 2024 Apr 5;26(4):653-669.
SCLC cell lines 0.04 µM to 0.49 µM 4 days JIB-04 significantly decreased the viability of SCLC cell lines, particularly in etoposide-resistant lines Oncogene. 2024 Sep;43(38):2885-2899.
PC-3 cells 260 nM 48 hours Evaluate the effect of JIB-04 on PC-3 cells, results showed that JIB-04 decreased EphA2 expression and increased the silencing efficiency of siEphA2. J Nanobiotechnology. 2021 Mar 8;19(1):71.
DU145 cells 260 nM 48 hours Evaluate the effect of JIB-04 on DU145 cells, results showed that JIB-04 decreased EphA2 expression and increased the silencing efficiency of siEphA2. J Nanobiotechnology. 2021 Mar 8;19(1):71.
Nalm6 cells 0.25 µM 72 hours JIB-04 increased the sensitivity of cells to dexamethasone-induced cell death Cell Death Dis. 2018 Oct 10;9(10):1038.
J-LAT A2 cells 1 µM JIB-04 treatment increases the local H3K36me3 level at LTR nuc-1 Nucleic Acids Res. 2019 Aug 22;47(14):7333-7347.
J-LAT 10.6 cells 0.25–1 µM JIB-04 treatment increased the percentage of GFP-positive cells Nucleic Acids Res. 2019 Aug 22;47(14):7333-7347.
J89GFP cells 0.25–1 µM JIB-04 treatment increased the percentage of GFP-positive cells Nucleic Acids Res. 2019 Aug 22;47(14):7333-7347.
A549 cells 25 nM 4 hours To evaluate the effect of JIB-04 on radiosensitivity, results showed that JIB-04 significantly increased the intrinsic radiosensitivity of these radioresistant cell lines Cell Rep. 2018 Oct 23;25(4):1040-1050. e5
H1299 cells 16 nM 4 hours To evaluate the effect of JIB-04 on radiosensitivity, results showed that JIB-04 significantly increased the intrinsic radiosensitivity of these radioresistant cell lines Cell Rep. 2018 Oct 23;25(4):1040-1050. e5

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice H358 and A549 lung cancer xenograft models Intraperitoneal injection or Oral 110 mg/kg (IP) or 55 mg/kg (oral) 2–3 times weekly for 5 weeks JIB-04 significantly inhibited the growth of H358 and A549 tumors and reduced tumor burden, while showing no significant effects on body weight or overall health of the mice. Nat Commun. 2013;4:2035.
Nude mice SCLC tumor xenograft model Oral 75 mg/kg Three times a week, for several weeks JIB-04 significantly inhibited the growth of SCLC tumor xenografts, with reduced tumor volume and weight Oncogene. 2024 Sep;43(38):2885-2899.
Nude mice Subcutaneous tumor model of H1299 cells Oral gavage 50 mg/kg/day Every other day for a total of 12 doses To evaluate the effect of combined JIB-04 and radiation therapy on tumor growth and survival, results showed that the combination significantly inhibited tumor growth and prolonged survival Cell Rep. 2018 Oct 23;25(4):1040-1050. e5

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.24mL

0.65mL

0.32mL

16.19mL

3.24mL

1.62mL

32.39mL

6.48mL

3.24mL

References

 

Historical Records

Categories